Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Goldman Sachs Group Inc Sells 105,807 Shares of Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Goldman Sachs Group Inc sold 105,807 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Goldman Sachs Group Inc also recently made the following trade(s):

• On Thursday, August 6th, Goldman Sachs Group Inc acquired 500,000 shares of Attovia Therapeutics stock. The stock was purchased at an average price of $17.00 per share, for a total transaction of $8,500,000.00.
• On Wednesday, August 5th, Goldman Sachs Group Inc acquired 85,000 shares of Attovia Therapeutics stock. The stock was purchased at an average cost of $21.00 per share, with a total value of $1,785,000.00.

Attovia Therapeutics Stock Up 6.2%

Shares of NASDAQ ATTO traded up $1.12 during midday trading on Thursday, reaching $19.18. 406,507 shares of the company’s stock were exchanged, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 52-week low of $16.15 and a 52-week high of $22.79.

Hedge Funds Weigh In On Attovia Therapeutics

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.